top of page

January 27th Newsletter

Check out all our latest updates

2021 is a new year full of new challenges and new innovations in the kidney world. This issue of the HDU newsletter focuses on some of those, including new treatment choices and new legislation. You can find these and more on the HDU Facebook groups and on Twitter.

Focus on Our Friends



Fabulous news from our friends at Quanta!  More choices for dialyzors!

Quanta Dialysis Technologies Ltd ("Quanta" or "the Company"), a British medical technology pioneer developing innovative dialysis products and services for the global market, today announces it has received 510(k) clearance from the US Food and Drug Administration ("FDA") to market its small and simple, high performance hemodialysis system SC+. This critical milestone enables Quanta to bring to the American market its portable device that can provide a dialysis dose equivalent to today's standard of care, but in a compact, easy-to-use format suitable for a range of care settings. "Kidney failure is one of the costliest health conditions for the American health system. The imperative for better value in healthcare, coupled with new challenges driven by COVID-19, has amplified the need to reimagine how hemodialysis is delivered across a variety of settings," said John E Milad, CEO, Quanta.


Our friends at The Kidney Project are developing a patient advisory board to make sure that the patient voice is front and center as the development of the artificial kidney continues.  Although the entire process of creating a whole new option for kidney patients is long and demanding, Dr. Shuvo Roy and his team are always focused on what patients want in a revolutionary device.

Currently, the Kidney Project is seeking advisory board members who have experience with a wide range of treatments.  Here is the link to apply:

The Kidney Project - Patient Advisory Board Application (

Noteworthy News


Another of the new machines is the Tablo, a small portable machine with many dialyzor friendly simpler options.  Tablo was designed to simplify dialysis, making it easier and more accessible for patients to take advantage of the safety, convenience and flexibility of dialyzing at home," Leslie Trigg, Outset Medical's CEO, said in a press release. "We are proud to offer them this new, life-enhancing option, particularly in light of the COVID-19 related challenges dialysis patients and providers are experiencing."

Here is a link to see dialyzor Tracey talk about her experience dialyzing at home with Tablo.



Although HDU's mission focuses on home dialysis modalities, we understand that many of our members will seek a transplant in the course of their journey.  Recently, the long awaited Immunosuppressive Drug Coverage bill was signed into law.  HDU, along with other organizations likr the American Kidney Fund,   has advocated for its passage for many years. Here is a link to the AKF press release:

American Kidney Fund Thanks President Trump for Signing End-of-Year Legislative Package that Includes Lifesaving Immunosuppressive Drug Coverage for Kidney Transplant Recipients - American Kidney Fund (AKF)


"Well, I always know what I want. And when you know what you want--you go toward it. Sometimes you go very fast, and sometimes only an inch a year. Perhaps you feel happier when you go fast. I don't know. I've forgotten the difference long ago, because it really doesn't matter, so long as you move."
- Ayn Rand, We the Living

 This interesting quote from author Ayn Rand certainly reflects the climate in the dialysis world.  Sometimes progress is fast, sometimes it is frustratingly slow.  The important thing is to keep moving forward to provide safe and effective treatments to improve the quality of life for those with kidney disease. 

bottom of page